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Abstract
Background: There exists a lack of knowledge regarding the quantity and quality of scientific yield in relation to individual
cancer types. We aimed to measure the proportion, quality and relevance of oncology-related articles, and to relate this
output to their associated disease burden. By incorporating the impact factor(IF) and Eigenfactor
TM(EF) into our analysis we
also assessed the relationship between these indices and the output under study.
Methods: All publications in 2007 were retrieved for the 26 most common cancers. The top 20 journals ranked by IF and EF
in general medicine and oncology, and the presence of each malignancy within these titles was analysed. Journals
publishing most prolifically on each cancer were identified and their impact assessed.
Principal Findings: 63260 (PubMed) and 126845 (WoS) entries were generated, respectively. 26 neoplasms accounted for
25% of total output from the top medical publications. 5 cancers dominated the first quartile of output in the top oncology
journals; breast, prostate, lung, and intestinal cancer, and leukaemia. Journals associated with these cancers were associated
with much higher IFs and EFs than those journals associated with the other cancer types under study, although these
measures were not equivalent across all sub-specialties. In addition, yield on each cancer was related to its disease burden
as measured by its incidence and prevalence.
Conclusions: Oncology enjoys disproportionate representation in the more prestigious medical journals. 5 cancers
dominate yield, although this attention is justified given their associated disease burden. The commonly used IF and the
recently introduced EF do not correlate in the assessment of the preeminent oncology journals, nor at the level of individual
malignancies; there is a need to delineate between proxy measures of quality and the relevance of output when assessing
its merit. These results raise significant questions regarding the best method of assessment of research and scientific output
in the field of oncology.
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Introduction
Proportional representation in the medical literature of
individual cancers and oncology as a whole has been difficult to
establish. The rapid increase in medical research publications has
been facilitated by the development of the internet, integrated
search engines, and on-line publishing. The two principal
repositories for medical research publications are the Web of
Science (WoS) (Thompson Reuters), and PubMed (the National
Library of Medicine (NLM)), the latter recognised as the most
frequently used source for information in the medical field [1].
Recently developed internet-based analytical tools now allow for
interrogation of these online databases and for the provision of
reports that are comparable within and between datasets.
Bibliometrics is a systematic method for evaluating research
output which can help map changes in the interest of a scientific
community over time, [2] and can provide insights into both
qualitative and quantitative research trends. The bibliometric
indicator most commonly used to undertake qualitative analysis is
the journal impact factor (IF) which is based on two elements; the
numerator, which is the number of citations in the current year to
items published in the previous 2 years, and the denominator,
which is the number of substantive articles and reviews published
in the same 2 years [3]. Despite its popularity, there are a number
of criticisms of the IF, particularly surrounding the ease with which
it may be manipulated by journals [4], and the lack of clarity
regarding what constitutes a ‘citable’ output [5]. It has further
been argued that the metric lacks normalisation for reference
practices across disciplines [6,7], and does not indicate the
relevance (the degree to which a journal publishes on a particular
topic or sub-specialty) of publications to a particular audience. In
contrast, the recently developed Eigenfactor
TM (EF), which ranks
journals according to the number and weight of incoming
citations, attempts to adjust for differences in ‘‘citation culture’’
between journals and across fields, and may provide an enhanced
level of discrimination [8].
Calculation of the EF is based on that which Google uses when
ranking web pages. This PageRank algorithm [9] regards the
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pages) as recommendations, with two extra comments: (1) the
status of the recommender is important, and (2) the recommen-
dation should drop in weight if the recommender is too generous
giving them. In short, a web page is important (gets a high
popularity score) if it is pointed to by other important (high ranked)
pages [10]. Instead of websites, the Eigenfactor algorithm scores
journals, and instead of using hyperlinks, it uses citations. By
simulating random traffic on a network these algorithms calculate
the popularity of journals in a self-consistent fashion. Its developers
claim that the resulting score provides an estimate of the
percentage of time that users spend with a particular journal,
with this amount of time postulated to be a measure of that
journal’s influence within the overall network of academic citations
[11]. The resulting rankings for journals have been published on
Eigenfactor.org since 2006 [11], and are now published as part
Thomson Reuter’s annual Journal Citation Report (JCR).
Bibliometric analysis has previously been employed as a method
of correlating research productivity in oncology with geographic
variation in output and funding [12,13], and the development of
translational research [14]. Investigation of output across a range
of disciplines within oncology has not been undertaken previously
however, nor has an attempt been made to relate this output to
proxy measures of quality such as the IF and EF. The principal
objective of this study therefore, was to measure the proportion,
quality and relevance of articles for the most common cancer
types. By incorporating the IF and EF into our analysis we also
aimed to assess the relationship between these bibliometric indices
and the research output under study.
Materials and Methods
Publications were retrieved by searching for each cancer using
its medical subject heading (MeSH) term in PubMed. The
subheadings encompassed by each MeSH term were then
employed to perform an equivalent search in the WoS database.
Numbers were obtained for English-language entries for each of
the malignancies under study. All peer-reviewed articles, including
editorials, reviews, technical notes and letters to the editors were
included.
Both PubMed and the WoS databases were consulted for the
reference period 01/01/2007 to 31/12/2007, with all searches
conducted between May and August 2009. Search results in the
WoS included entries from the ‘‘Science Citation Index-Expand-
ed’’ and the ‘‘Social Sciences Citation’’ indices, yielding 126845
articles. Search results for PubMed, which covers Medline and
other specialised databases within the National Library of
Medicine (NLM), and catalogues entries from 6000 journals,
yielded 63260 articles.
The 26 cancers with the highest incidence as defined by the
Surveillance, Epidemiology, and End Results (SEER) database of
the National Cancer Institute (NCI) in 2006 were included in the
study (Table S1) [15]. The cancer with the 27th highest incidence
in this database was that involving bone; this was not included due
to the potential confounding influence of publications relating to
bone metastases on our analysis.
Three collections of journals were included in this analysis.
Cluster A (Table S2):
AIF-The top 20 medical journals ranked by impact factor, 2007
AEF-The top 20 medical journals ranked by eigenfactor, 2007
Cluster B (Table S2):
BIF-The top 20 oncology journals ranked by impact factor, 2007
BEF-The top 20 oncology journals ranked by eigenfactor, 2007
Cluster C (Table S3):
The ten journals which published most prolifically on each of
the 26 cancers.
Clusters A and B were identified in the 2007 edition of
Thomson Reuter’s JCR, and cluster C was identified using the
cloud-based web service PubReminer [16].
In order to assess scientific yield relative to disease burden, a
publication ratio was derived using a method described by Al
Shahi et al. in 2001 [17]. Briefly, we divided the number of
Pubmed papers published in 2007 about each cancer by a measure
of its disease burden (incidence or prevalence). Incidence and
prevalence data were obtained from the SEER database [15].
Each relevant bibliographic record was downloaded and then
evaluated and assessed using Microsoft Excel spreadsheet software,
and Statistical Package for Social Science version 15.0 (SPSS Inc,
Chicago, Illinois, USA) software. The relationship between IF and
EF values was investigated using the Spearman correlation
coefficient and Kruskal-Wallis between groups analysis; a p value
of less than 0.05 was deemed statistically significant.
Results
Publications on the 26 cancers under study accounted for 8.19%
(63260/772243) of output in PubMed, and 8.04% of output in
WoS (126845/1576018). Breast cancer accounted for the highest
percentage of oncology publications in both Pubmed (13?81%)
and the WoS (13?83%) (Table 1). Other high publication rate
cancer subjects (present in the top quartile of output for both
databases) included lung cancer, leukaemia, intestinal cancer, and
prostatic cancer.
Oncology related articles constituted 25% of all publications in
the top 20 medical journals according to IF (AIF, Oncology
articles/total articles: 3096/12399) and EF (AEF, Oncology
articles/total articles: 4689/18431) (Table 2). Almost two thirds
of these articles related to just 6 cancers: prostate, breast, intestinal,
lung, non-hodgkin lymphoma, and leukaemia (AIF, 65.5%, 2027/
3096; AEF, 63.6%, 2982/4689).
Articles relating to the 26 cancers with the highest incidence
constituted 53% and 72% of all publications in the top 20
oncology journals according to IF (BIF, 5086/9527) and EF (BEF,
8775/12209), respectively (Table 3). Two thirds of these articles
were related to just 7 cancers: breast, prostate, lung, intestinal
cancer, leukaemia, ovarian cancer and cancers involving the CNS
(BIF, 63.5%, 3230/5086; BEF, 65.5%, 5746/8775).
Figure 1(a) demonstrates the results of running our publication :
incidence ratio. When research output is related to the actual
incidence of each cancer, leukaemia and cancers involving the
liver and central nervous system (CNS) appear overrepresented.
The publication ratio for the latter, for example, was approx-
imately 23-fold greater than that for prostate cancer and almost
10-fold greater than that for breast cancer. This is again
highlighted in Figure 1(b), where cancer incidence is plotted
against the percentage contribution to the overall research yield
contributed by each cancer in 2007. Output was next assessed
relative to associated disease prevalence. Cancers involving the
liver and pancreas were markedly overrepresented (Figure 2(a)),
with the publication ratio for the former more than 70-fold and
40-fold greater than that for prostate or breast cancer, respectively;
similarly, when each cancer’s percentage contribution to the total
output is plotted against associated disease prevalence, it is evident
that liver cancer and cancers involving the CNS are associated
with high levels of research yield (Figure 2(b)).
The top 5 oncology journals by IF and by EF were in the top 10
most frequently publishing journals for 11 and 18 of the
malignancies under study, respectively (Table S3). The journals
Research Output in Oncology
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the Journal of Clinical Oncology (n=11), the Annals of Surgical Oncology
(n=11), and Clinical Cancer Research (n=9).
The ten journals which published most prolifically on each
cancer (cluster ‘C’) generated 16219 articles on the 26 cancers of
interest in 2007 (Table S3). Over half of these articles were related
to just 6 cancer sites: breast, leukaemia, prostate, lung, intestinal
cancer, and cancers involving the CNS (n=8570; 52%) (Table 4).
There was no correlation between the total output of these
journals and either the IF (p=0.073) or the EF (p=0.053).
Hodgkin lymphoma, melanoma, lung and prostate cancer were
located in the top quartile by both IF and EF, whilst cancers of the
gallbladder, vulva, larynx and mouth were located in the lowest
quartile by both measures. Significant differences were noted in
the IFs and EFs of those cancers located in the upper quartile
versus those in the lowest (median IF upper quartile 4.45 (IQR
4.20–4.61) versus median IF bottom quartile 1.66 (IQR 1.37–
2.13), p=0.000; median EF upper quartile 0.0515 (IQR 0.0451–
0.0715) versus median EF lower quartile 0.0136 (IQR 0.0108–
0.0187), p=0.000).
As expected, there was a strong correlation between the EF and
the IF in the general medical literature (r=0.854, p=0.000)
(Figure 3), and this relationship was maintained in the top 20
journals by IF and EF (r=0.674, p=0.001). Strong correlation
was also noted between EF and IF scores in the oncology literature
(r=0.725, p=0.000) (Figure 4); this was not maintained in the
highest impact journals (Groups BIF and BEF), however
(r=0.289, p=0.217).
Discussion
The relationship between a medical specialty or condition and
its associated research output, with respect to volume and ‘quality’,
is complex and may be dependent on such diverse influences as
funding, socio-political influence and disease causation [18]. This
complexity notwithstanding, the journal IF is increasingly used as
a simple proxy measure of research productivity. Despite concerns
that it was neither designed nor intended for this purpose, research
funding is now frequently dependent upon it. Furthermore, the
independence and objectivity of a commercially driven measure
has been questioned. Until recently there was no viable alternative
to the IF; the development of the EF at least offers stakeholders
within the various scientific and medical disciplines an opportunity
to assess research yield from a different perspective.
Table 1. Number (Percentage) of Publications For Neoplasms In PubMed and the Web of Science (WoS).
PubMed WoS
Quartile Rank Cancer Output (%) Rank Cancer Output (%)
1 1 Breast 8736 (13.81) 1 Breast 17563 (13.83)
1 2 Intestinal 6304 (9.97) 2 Intestinal 11305 (8.91)
1 3 Lung 5127 (8.10) 3 Lung 11237 (8.86)
1 4 Leukemia 4762 (7.53) 4 Leukemia 10226 (8.06)
1 5 Prostatic 4606 (7.28) 5 Pancreatic 9118 (7.19)
1 6 CNS 4106 (6.49) 6 Prostatic 8573 (6.76)
2 7 Liver 3877 (6.13) 7 Liver 7091 (5.59)
2 8 Uterine 3181 (5.03) 8 CNS 6664 (5.25)
2 9 Lymphoma 2801 (4.43) 9 Lymphoma 5270 (4.15)
2 10 Melanoma 2371 (3.75) 10 Kidney 4563 (3.60)
2 11 Ovarian 2235 (3.53) 11 Melanoma 4398 (3.47)
2 12 Stomach 1938 (3.06) 12 Ovarian 4153 (3.27)
2 13 Pancreatic 1937 (3.06) 13 Soft Tissue 3826 (3.02)
2 14 Kidney 1788 (2.83) 14 Mouth 3348 (2.64)
3 15 Mouth 1545 (2.44) 15 Stomach 3143 (2.48)
3 16 Urinary 1208 (1.91) 16 Hodgkin 3130 (2.47)
3 17 Esophageal 1191 (1.88) 17 Myeloma 2683 (2.12)
3 18 Thyroid 1182 (1.87) 18 Uterine 2378 (1.87)
3 19 Soft Tissue 1112 (1.76) 19 Urinary 2259 (1.78)
3 20 Myeloma 1085 (1.72) 20 Thyroid 1991 (1.57)
4 21 Testicular 568 (0.90) 21 Esophageal 1454 (1.15)
4 22 Hodgkin 500 (0.79) 22 Testicular 1017 (0.80)
4 23 Laryngeal 442 (0.70) 23 Mesothelioma 567 (0.45)
4 24 Mesothelioma 336 (0.53) 24 Laryngeal 526 (0.41)
4 25 Gallbladder 163 (0.26) 25 Gallbladder 213 (0.17)
4 26 Vulvar 159 (0.25) 26 Vulvar 149 (0.12)
Total 63260 (100) Total 126845 (100)
Neoplasms are listed in order of their decreasing contribution to the overall research output for the 26 neoplasms in each database, in 2007.
doi:10.1371/journal.pone.0013902.t001
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8% of the output of medical journals in 2007, it represented 25% of
output from the highest IF and EF journals. This disproportionate
representation of oncology topics in more prestigious journals has
been suggested before [19]; that these articles are dominated by a
small number of cancers is a novel finding, however.
This level of bias to specific cancers is not limited to the general
medical journals. Publications relating to prostate, breast, lung,
and intestinal cancer, and leukaemia, accounted for over half of
the total output in the top medical oncology journals. Analysis of
the top 10 most prolific journals for each cancer reveals a similar
picture; the journals publishing most frequently on these cancers
are associated with much higher IF and EF scores.
It may be a source of concern for those working in less
fashionable areas of oncology that a small number of cancers
dominate the scientific yield. This domination notwithstanding
however, our results support the argument that, relative to their
impact on society, 4 of these cancers - breast, prostate, lung and
intestinal - are actually underrepresented, with research interest in
many of the rarer malignancies disproportionately greater.
Furthermore, as much as 60% of cancer research is not ‘site
specific’ and hence may hold relevance for all types of cancer [20].
In addition, whilst we focus on the relationship between disease
burden and research output, there are many other influences on
the level of research interest in a given area, including scientific
opportunity; researchability; potential for progress; fundraising
(certain tumours might attract more public donations than others);
and the quality and size of the research workforce in different
areas [20].
Our results have demonstrated that whilst there is significant
correlation between the IF and EF in the oncology literature as a
whole, differences exist both for the high impact oncology journals
and at the level of individual cancers. If one measures article value
on IF alone, then the highest-ranking oncology journal would be
CA: A Cancer Journal For Clinicians. In contrast, Cancer Research is the
highest-ranking oncology journal by EF (with CA: A Cancer Journal
for Clinicians not making the top 20 oncology journals).
Table 3. Number (Percentage) of Publications in the top 20
oncology journals ranked by IF and EF for 26 most common
neoplasms.
BIF BEF
Rank Cancer Output (%) Rank Cancer Output (%)
1 Breast 833 (16.38) 1 Breast 1595 (18.18)
2 Leukemia 638 (12.54) 2 Intestinal 895 (10.20)
3 Intestinal 511 (10.05) 3 Lung 862 (9.82)
4 Lung 497 (9.77) 4 Prostatic 851 (9.69)
5 Prostatic 489 (9.61) 5 Leukemia 759 (8.64)
6 CNS 262 (5.15) 6 Ovarian 398 (4.54)
7 Non-Hodgkin 246 (4.84) 7 CNS 386 (4.40)
8 Ovarian 239 (4.70) 8 Non-Hodgkin 373 (4.25)
9 Melanoma 199 (3.91) 9 Uterine 339 (3.86)
10 Liver 174 (3.42) 10 Liver 333 (3.79)
11 Pancreatic 160 (3.15) 11 Melanoma 321 (3.66)
12 Kidney 140 (2.75) 12 Pancreatic 278 (3.17)
13 Myeloma 128 (2.52) 13 Stomach 225 (2.56)
14 Uterine 119 (2.34) 14 Kidney 217 (2.47)
15 Stomach 91 (1.79) 15 Myeloma 166 (1.89)
16 Esophageal 71 (1.40) 16 Esophageal 160 (1.82)
17 Urinary 66 (1.30) 17 Urinary 141 (1.60)
18 Thyroid 45 (0.88) 18 Mouth 98 (1.11)
19 Hodgkin 44 (0.87) 19 Hodgkin 89 (1.01)
20 Testicular 40 (0.79) 20 Testicular 74 (0.84)
21 Mouth 32 (0.63) 21 Thyroid 73 (0.83)
22 Mesothelioma 27 (0.53) 22 Mesothelioma 51 (0.58)
23 Soft Tissue 23 (0.45) 23 Soft Tissue 42 (0.48)
24 Laryngeal 9 (0.18) 24 Laryngeal 36 (0.41)
25 Gallbladder 2 (0.04) 25 Gallbladder 9 (0.10)
26 Vulvar 1 (0.02) 26 Vulvar 4 (0.05)
Total 5086 Total 8775
BIF, output on each malignancy in the top twenty oncology journals by IF in
2007; BEF, output on each malignancy in the top twenty oncology journals by
EF in 2007.
doi:10.1371/journal.pone.0013902.t003
Table 2. Number (Percentage) of Publications in the top 20
medical journals ranked by IF and EF for 26 most common
neoplasms.
AIF AEF
Rank Cancer Output (%) Rank Cancer Output (%)
1 Leukemia 533 (17.22) 1 Breast 732 (15.61)
2 Breast 496 (16.02) 2 Leukemia 646 (13.78)
3 Intestinal 348 (11.24) 3 Lung 493 (10.51)
4 Lung 266 (8.59) 4 Intestinal 482 (10.28)
5 Non-Hodgkin 214 (6.91) 5 Prostatic 353 (7.53)
6 Prostatic 170 (5.49) 6 Non-Hodgkin 276 (5.89)
7 Liver 162 (5.23) 7 CNS 208 (4.44)
8 Myeloma 123 (3.97) 8 Ovarian 205 (4.37)
9 CNS 105 (3.39) 9 Melanoma 194 (4.14)
10 Ovarian 86 (2.78) 10 Liver 165 (3.52)
11 Pancreatic 86 (2.78) 11 Myeloma 156 (3.33)
12 Stomach 81 (2.62) 12 Pancreatic 151 (3.22)
13 Uterine 73 (2.36) 13 Kidney 112 (2.39)
14 Kidney 61 (1.97) 14 Uterine 109 (2.32)
15 Hodgkin 60 (1.94) 15 Stomach 80 (1.71)
16 Melanoma 60 (1.94) 16 Hodgkin 65 (1.39)
17 Esophageal 48 (1.55) 17 Esophageal 54 (1.15)
18 Testicular 38 (1.23) 18 Urinary 48 (1.02)
19 Soft Tissue 29 (0.94) 19 Testicular 36 (0.77)
20 Urinary 21 (0.68) 20 Thyroid 35 (0.75)
21 Mesothelioma 11 (0.36) 21 Soft Tissue 30 (0.64)
22 Mouth 11 (0.36) 22 Mouth 26 (0.55)
23 Thyroid 9 (0.29) 23 Mesothelioma 24 (0.51)
24 Laryngeal 5 (0.16) 24 Laryngeal 6 (0.13)
25 Gallbladder 0 (0.00) 25 Gallbladder 2 (0.04)
26 Vulvar 0 (0.00) 26 Vulvar 1 (0.02)
Total 3096 (100) Total 4689 (100)
AIF, output on each malignancy in the top twenty medical journals by IF in
2007; AEF, output on each malignancy in the top twenty medical journals by EF
in 2007.
doi:10.1371/journal.pone.0013902.t002
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on individual malignancies; for example, publications relating to
testicular and renal cancers are published most frequently in high
EF, but lower IF journals. In contrast, breast cancer, which has a
high IF for the ten journals which published most frequently on it,
is associated with a comparatively low EF score. Given that
scientific impact is a multidimensional construct, the difference in
IF and EF ranking may be an effect of relevance rather than
quality of the article searched.
The top 5 oncology journals by EF in 2007 included at least one
of the ten most prolific journals for 18 of the 26 cancers. The top 5
oncology journals by IF, however, published prolifically on just 11
of the 26 commonest cancers. What is the reason for this
difference? The developers of the EF score described it as ‘‘the
result of a random walk through the scientific literature. The
algorithm corresponds to a basic model of research in which
readers follow chains of citations as they move from journal to
journal…..Because of the structure of the citation network, our
model researcher will frequently visit large, important journal-
s….and will seldom visit small journals in the lowest tiers of the
publishing hierarchy’’ [8]. Our data demonstrates that those who
choose to employ the EF as their discriminator will identify
journals covering a greater breath of cancer topics than those
identified using the IF, and suggests that the EF is not just an index
of quality, but also functions as a measure of relevance, at least
within oncology as a whole.
The above analysis notwithstanding, researchers need to be
aware of the fact that literature regarding certain cancers may be
limited to low ranking journals according to standard proxy
measures. This may not be a reflection of the quality of the output
Figure 1. Number and Percentage of Publications, Relative to Cancer Incidence. (a) Publication ratios for 26 most common cancers,
ordered by their incidence (b) Percentage of Total Publications Versus Cancer Incidence.
doi:10.1371/journal.pone.0013902.g001
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demonstrated the breadth of journal titles responsible for output in
oncology and has identified which journals are most prolific in
which sub-specialties. Even the most wide-ranging journals
published on less than half of the 26 cancers included in this
analysis; it is thus clear that, for many, a reliance on quality
indicators, including the EF, in choosing which journals to search
will result in poor retrieval of the most relevant information, and
those involved in this process thus need to be cognisant of the
situation within their particular sub-specialty.
This work has a number of limitations. Whilst bibliometric
indicators can provide an interesting overview of scientific yield for
a given subject area, they are nevertheless just proxy measures,
and cannot replace the gold standard of reading each article and
journal individually to assess their quality or otherwise. We
examined English-language entries only; this obviously has
implications for those cancers which have a greater disease burden
in non-english speaking areas, wherein research output on those
topics might be much greater and introduces a level of bias into
our results. Furthermore, it should be noted that our study was
limited to a single year and, whilst we tried to ensure that our
searches were equivalent across the databases, it was not possible
to ensure absolute uniformity in the search strategies used; hence
the figures should be viewed in the context of the overall picture,
rather than in absolute terms. In addition, our work does not
concentrate specifically on research articles only, which some
would argue to have been preferable, although we believe our
search strategy gives a better indication of overall interest within
each sub-discipline of oncology. Finally, our analysis of the 132
journals within the category ‘Oncology’ was based on the list
Figure 2. Number and Percentage of Publications, Relative to Cancer Prevalence. (a) Publication ratios for 23 most common cancers,
ordered by their prevalence. Prevalence data was not available for 3 of the cancers; cancer of the gallbladder, vulva, and those involving the soft
tissue and heart, (b) Percentage of Total Publications Versus Cancer Prevalence.
doi:10.1371/journal.pone.0013902.g002
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Output IF EF
Cancer Output Rank
IF
Median (IQR) Rank
EF
Median (IQR) Rank
Breast 1890 1 4.50 (3.47–3.57) 3 .0407 (0.0157–0.1707) 9
Leukaemia 1757 2 3.75 (2.01–7.92) 10 .0254 (0.0132–0.1238) 18
Prostatic 1505 3 4.17 (2.60–5.79) 6 .0643 (0.0272–0.1410) 2
Lung 1273 4 4.22 (2.02–6.61) 5 .0931 (0.0286–0.2324) 1
Intestinal 1144 5 4.04 (2.08–5.29) 7 .0374 (0.0171–0.1707) 13
CNS 1001 6 1.92 (1.08–3.33) 23 .0385 (0.0082–0.0525) 12
Uterine 895 7 2.77 (1.35–4.36) 17 .0424 (0.0104–0.0874) 8
Ovarian 708 8 3.62 (1.24–6.61) 12 .0440 (0.0038–0.2324) 7
Liver 690 9 2.42 (1.97–6.90) 20 .0182 (0.0116–0.0660) 22
Non Hodgkin 676 10 4.68 (2.30–7.92) 1 .0396 (0.0127–0.1238) 10
Kidney 517 11 3.40 (1.54–5.79) 14 .0451 (0.0090–0.1310) 5
Mouth 495 12 1.40 (1.13–1.63) 25 .0109 (0.0051–0.0189) 25
Urinary 438 13 2.66 (1.79–4.57) 18 .0340 (0.0053–0.1104) 15
Melanoma 437 14 4.41 (2.69–6.29) 4 .0487 (0.0116–0.2188) 4
Stomach 437 15 3.17 (1.50–4.36) 16 .0203 (0.0172–0.0758) 21
Pancreatic 431 16 3.92 (2.18–6.07) 8 .0388 (0.0136–0.1611) 11
Myeloma 388 17 3.75 (2.30–6.42) 9 .0254 (0.0127–0.0937) 18
Thyroid 306 18 3.30 (2.93–4.37) 15 .0231 (0.0140–0.0271) 20
Esophageal 271 19 2.30 (1.55–5.94) 21 .0347 (0.0200–0.0692) 14
Laryngeal 203 20 1.29 (0.63–1.85) 26 .0117 (0.0058–0.0218) 24
Soft tissue 190 21 2.47 (1.87–3.98) 19 .0279 (0.0132–0.0590) 16
Testicular 176 22 3.55 (1.95–8.09) 13 .0451 (0.0061–0.1612) 5
Hodgkin 162 23 4.59 (2.63–6.86) 2 .0544 (0.0213–0.1712) 3
Mesothelioma 88 24 3.69 (1.83–5.03) 11 .0266 (0.0049–0.0876) 17
Vulvar 84 25 1.43 (0.98–2.08) 24 .0106 (0.0050–0.0179) 26
Gallbladder 57 26 2.07 (1.57–2.35) 22 .0155 (0.0112–0.0224) 23
By EF, titles publishing most frequently on testicular and kidney neoplasms were joint 5th, and leukaemia and myeloma joint 18th. IQR = Interquartile range.
doi:10.1371/journal.pone.0013902.t004
Figure 3. Impact Factor Versus Eigenfactor, General Medical
Journals. IF,EF scores, 100 titles in ‘medicine, general and internal’, JCR
2007. Top journals, by IF = New England Journal of Medicine (NEJM),
Lancet, Journal of American Medical Association (JAMA), Annals of
Internal Medicine, & Annual Review of Medicine. Top 5, by EF = NEJM,
Lancet, JAMA, British Medical Journal (BMJ) and Annals of Internal
Medicine.
doi:10.1371/journal.pone.0013902.g003
Figure 4. Impact Factor Versus Eigenfactor Scores, Oncology
Journals. IF,EF scores for 132 titles in category ‘oncology’, JCR 2007.
Top 5 journals, by IF = Ca:Cancer Journal Clinicians, Nature Reviews
Cancer, Cancer Cell, the Journal of the National Cancer Institute, and the
Journal of Clinical Oncology (JCO). Top 5, by EF = Cancer Research, the
JCO, Oncogene, Clinical Cancer Research, and Nature Reviews Cancer.
doi:10.1371/journal.pone.0013902.g004
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noted that an alternative list could have been used based on the
SCImago Journal Rank indicator (SJR) which is calculated within
Scopus (Elsevier), but it has been previously demonstrated that
those oncology journals indexed in Scopus which are not covered
by the JCR tend to have low to very low impact factors.[21]
The controversy surrounding the use of bibliometric indicators
notwithstanding, this analysis has demonstrated the privileged
position which oncology holds in the medical literature. This
preferential bias is not extended uniformly across the oncological
spectrum and this heterogenicity requires closer scrutiny.
It is clear that the commonly used IF and the recently
introduced EF do not correlate for the preeminent oncology
journals, nor do they correlate at the level of individual cancers.
Researchers should be aware that selection of one measure over
the other as a proxy evaluation of quality may significantly change
the strength of, for example, a grant proposal.
Finally, our results also suggest that the most relevant
information for those working in many of the oncologic sub-
specialties is not necessarily to be found in the most prestigious
journals as delineated by proxy indicators of quality. This article
raises significant questions regarding the best method of
assessment of research and scientific output in the field of
oncology.
Supporting Information
Table S1 Incidence of Neoplasms, per 100,000 population, and
Search Strategies Employed. Malignancies listed in decreasing
order of incidence, as defined by the SEER Database, 2006. Rates
are age-adjusted to the 2000 US standard population. TS =
Topic subject.
Found at: doi:10.1371/journal.pone.0013902.s001 (0.07 MB
DOC)
Table S2 Top 20 Journals by Impact Factor and Eigenfactor.
*Categories included in analysis of the top 20 medical journals =
Gastroenterology and Hepatology; Haematology; Medicine, Ge-
neral & Internal; Medicine, Research & Experimental; Obstetrics
and Gynaecology; Oncology; Orthopaedics; Otorhinolaryngology;
Pathology; Paediatrics; Radiology, Nuclear Medicine & Medical
Imaging; Respiratory System; Surgery; Transplantation; Urology
& Nephrology.
Found at: doi:10.1371/journal.pone.0013902.s002 (0.06 MB
DOC)
Table S3 Top 10 Publishing Journals, per Malignancy, 2007.
Where journals were responsible for an equivalent number of
entries in tenth position, all are named. Calculations of median
impact- and Eigenfactors were based on the ten journals with the
highest ratings.
Found at: doi:10.1371/journal.pone.0013902.s003 (0.19 MB
DOC)
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